General information
Atriva Therapeutics GmbH
Eisenbahnstr. 1
72072 Tübingen, Baden-Württemberg
Germany
Contact person: Rainer Lichtenberger, Chief Executive Officer
Company main phone: +49 (7071) 8597673
Website: https://www.atriva-therapeutics.com
Year founded: | 2015
|
Source of foundation: | Spin-off from university |
Name of foundation source: | Universities of Giessen, Münster and Tübingen |
Corporate description / mission:
Atriva Therapeutics GmbH is a biopharmaceutical company that developing inhibitors against respiratory viral infections. Atriva’s lead product Zapnometinib in Phase 2b (ATR-002) is a host-targeting agent which inhibits viral replication in SARS-COV2, influenza, hantavirus, dengue virus among others and favorably modulates the body’s immune response.
State of ownership: Private / independent
Headquarters: Yes
Categorization
Sector: |
- Biotechnology - Therapeutics and Diagnostics
|
Subsector: |
- Anti-infectives
- Small molecules
|
Primary therapeutic areas: |
- Infectious and parasitic diseases / infectiology / parasitology
- Respiratory / pulmonology
|
Customer segments: |
- Hospitals
- Large biotech & big pharma
|
Distribution: |
- Indirect (independent dealer)
|
Summary Products / Services / Technologies
Number of Biotech Products
Pre-clinical: | 3 | |
Phase I: | 1 | |
Phase II: | 2 | |
Phase III: | 6 | |
Description of products:
ATR-002
Special IP situation:
The company owns eleven broad patent families with broad coverage related to the use of MEK inhibitors and other kinase inhibitors for anti-viral therapies. The patent life runs through 2041
Technology used:
Atriva product platform is based on MEK kinase inhibitors focusing on severe viral infections and applicable for use with high-risk COVID-19 and influenza patients.
Financing details
Money raised to date: | EUR 37.00M | |